Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 40.6% from a year ago
Other current assets stood at $7.86M at the end of Q1 FY2026, up 40.6% from a year earlier and down 2.1% from the prior quarter.
Context
- Other current assets amounted to 1.6% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +40.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 8.02M USD
- Year-over-year change
- +77.4%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.02M | +77.4% |
| FY2024 | 2024-12-31 | 4.52M | +33.2% |
| FY2023 | 2023-12-31 | 3.39M | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Current Assets vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 other current assets of $7.86M is the 4th highest of the 10 companies compared; the peer median is $6.36M.
- Its year-over-year change of +40.6% is the 3rd highest of 6, against a peer median of +15.4%.
- Other current assets amounts to 1.6% of total assets for RAPP, versus a peer median of 2.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $90.6M | — | — | 5.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $20.8M | — | +976.7% | 5.3% |
| Mar 2026 | $17.12M | — | +64.9% | 4.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $7.86M | +40.6% | — | 1.6% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $6.64M | +366.0% | +63.3% | 2.5% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $6.36M | +15.4% | +443.0% | 4.1% |
| Mar 2026 | $5.36M | +23221.7% | — | 1.9% | |
| Mar 2026 | $1.03M | — | — | 2.8% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | +69.9% | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $6.36M | +15.4% | +69.9% | 2.8% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.